Emerging Therapies in the Management of High-Grade Serous Ovarian Carcinoma: a Focus on PARP Inhibitors

AbstractPurpose of ReviewThe aims of this review are to describe key clinical trials that led to Federal Drug Administration (FDA) approval of poly(ADP-ribose) polymerase (PARP) inhibitors for ovarian cancer treatment, contextualize current indications, and to present future perspectives on the use of PARP inhibitors in this setting.Recent FindingsSince 2014, the FDA has approved three PARP inhibitors for the treatment of relapsed ovarian cancer, initially for patients with BRCA mutations and more recently, for a broader patient population.SummaryHigh-grade serous ovarian carcinomas (HGSOC) account for more than 70% of epithelial ovarian cancers. DNA repair is frequently defective in these cancers, and homologous recombination pathway defects are present in approximately 50% of cases. The ...

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2tprbYx
via IFTTT